maintain outperform rate share gilead
follow review result reduc price target
slightli reduc ep
continu strong growth hiv sale better expect switch
next-gener brand consider oper leverag
expect beat estim beyond
particular focu product address gap mid-to-
late stage asset believ anchor current
spend appropri consid extern asset fill gap
multipl lever go improv product
gilead report oper result yesterday
market close provid updat key product pipelin
initi non-gaap ep in-lin consensu
total revenu vs consensu overal hiv product
sale in-lin consensu hcv sale
yescarta car-t sale slightli consensu
focu key product trend highlight global hiv sale
growth year-over-year yoy sequenti
driven primarili new product launch includ biktarvi
treatment truvada descovi prep within us
treatment market highlight new patient add
treatment naiv patient switch includ
legaci brand competitor gsk hcv sale
declin continu expect sale
highlight greater predict trend actual stabil
us author gener yescarta car-t sale
reflect quarter-to-quart variabl rel flat yoy
addit focu pipelin product
highlight complet regulatori file eu japan
inhibitor filgotinib rheumatoid arthriti complet
file recent initi phase trial filgotinib
psoriat arthriti intend initi phase trial ankylos
spondyl data phase ulcer coliti trial
expect phase crohn diseas trial complet
enrol american societi hematolog meet
present data registr trial
report week nash data atla trial evalu fxr
agonist inhibitor firsocostat monotherapi
combin also report week data
agonist selagatimod hbv infect
compani data secur llc estim reuter
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
non-gaap ep
product sale
total revenu
invest vs ye
cfo debt paydown
dividend
repurchas stock
paid galapago
product sale expect rang
non-gaap gross margin remain
non-gaap expect rang
non-gaap sg expect rang
effect tax rate remain
impact non-gaap adjust remain
global net product sale sequenti yoy
us sale sequenti yoy
eu sale sequenti yoy
row sale flat sequenti yoy
sequenti declin attribut one-tim adjust
hiv product result trend
global net sale sequenti yoy
us sale sequenti yoy demand growth
eu sale sequenti yoy
intern sale yoy
hiv treatment describ account patient vs prep
new patient start describ switch treatment naiv patient switch
gsk dolutegravir come product
truvada prep describ key driver hiv sale growth account us sale
patient current treat prophylaxi
recent approv descovi prep earlier octob highlight increment driver
hcv product result trend
global net sale sequenti yoy
us sale sequenti yoy
eu sale sequenti yoy
highlight believ predict pattern declin hcv trend
cell therapi result trend
global yescarta sale repres growth yoy sequenti
us yescarta sale sequenti yoy
eu yescarta sale sequenti
challeng reimburs environ highlight car-t elig patient opt clinic trial
highlight key contributor lumpi car-t sale
note recent approv descovi pre-exposur prophylaxi prep file eu us
expect center diseas control estim approxim peopl
would benefit prep current approxim number prep recal show
equival efficaci descovi improv bone renal safeti profil descovi approv
prep exclud cisgend women conduct studi popul
highlight first-in-class inject hiv capsid inhibitor receiv breakthrough
therapi design fda treatment highli treatment-experienc patient given everi
month dose evalu potenti inject partner drug could combin
creat long-act multidrug regimen note priorit
nucleosid revers transcriptas inhibitor nrti prodrug also evalu patient
complet regulatori file inhibitor filgotinib rheumatoid arthriti eu
japan complet file
forthcom american colleg rheumatolog meet provid updat
trial filgotinib patient fail prior biolog therapi well safeti updat across
filgotinib ra program
compani continu advanc filgotinib indic includ ulcer coliti phase data
crohn diseas complet phase enrol initi phase ankylos
spondyl phase trial psoriat arthriti recent initi also note filgotinib
combin inhibitor lanreplenib btk inhibitor tirabutinib achiev level efficaci
requir advanc drug sjorgen combin filgotinib plu lanreplenib
cutan lupu still list lanreplenib pipelin tirabrutinib
american societi hematolog present surviv data trial
yescarta diffus larg cell lymphoma also present data registr enabl
trial yescarta sibl mantl cell lymphoma note trial
compar yescarta autolog stem cell transplant line dlbcl complet enrol
re-commit file ind allogen car-t product
remain pipelin phase initi legaci cell therapi program
mage cell receptor hpv cell receptor schedul complet enrol
non-alcohol steatohepat report top-lin week data later atla trial
evalu fxr agonist cilofexor monotherapi acetyl-coa carboxylas inhibitor firsocostat
monotherapi doublet cilofexor firsocostat expect data doublet
combin novo glucagon-lik receptor agonist ozemp
hepat expect data week phase dose escal trial agonist
selagatimod monotherapi combin vemlidi
price target
arriv price target appli multipl ep estim risk includ continu
slow hcv patient volum emerg credibl competit threat merck particular failur
key pipelin program hbv nash failur secur meaning revenu opportun
expect earn growth reacceler beyond continu hiv product growth
increment contribut galapagos-partnership program fibrosi inflamm
larg cap global commercial-stag biotechnolog compani discov develop small
molecul biolog drug global leadership hiv hcv expand beyond infecti
diseas liver diseas oncolog inflammation/fibrot diseas
